All News

The FDA is taking action against companies that claim to treat or prevent the virus.

Health care spending increased by 4.4% in 2018, slightly more than the 4.2% increase in 2017, and the third consecutive year with an increase greater than 4%.

Due to the uniqueness of each disease state and motivations of each player in the market to capture revenue from the growing industry, there is an abundance of specialty pharmacy solutions available in the market.

The law makes New Mexico the third state to enact a co-pay cap for insulin.

Regular use of fish oil dietary supplements has been linked to a lower risk of premature death and cardiovascular disease, such as heart attacks and strokes.

Top news from across the health care landscape.

Levitating human plasma may lead to simpler detection of diseases and the development of addiction to substances such as opioids.

Rotovirus infection is a hypothesized risk factor for type 1 diabetes, according to the authors.

Chronic fibrosing ILD with a progressive phenotype encompasses a group of fibrotic lung diseases caused by various underlying diseases or conditions.

Top news from across the health care landscape.

Could losartan be the cause of insomnia?

The FDA also granted osilodrostat orphan drug designation.

One of the most important goals for a pharmacy owner is to optimize their gross profit per script and to navigate direct and indirect remuneration (DIR) fees through medication adherence.

Treatment with cord blood-derived chimeric antigen receptor natural killer-cell therapy targeting CD19 resulted in clinical responses in relapsed or refractory non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.

Top News of the Week from Directions in Specialty Pharmacy

Top news from across the health care landscape.

The New Mexico House and Senate recently passed a bill that would require insurance companies to reimburse pharmacists who provide clinical services and prescribe medications.

Gilead has agreed to pay $95.50 per share in cash for Forty Seven Inc, adding the 5-year old biotechnology company to bolster its portfolio of oncology drugs.